ea0081oc4.6 | Oral Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022
Gadelha Monica R
, Randeva Harpal
, Gordon Murray B
, Mezosi Emese
, Doknic Mirjana
, Toth Miklos
, Boguszewski Cesar L
, Nichols Melissa
, Jochelson Theresa
, Henley Scott
, Patel Meenal
, Mendez Debbie Koh
, Ferrara-Cook Christine
, Krasner Alan
, Casagrande Alessandra
, Struthers R Scott
Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...